These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 204621)

  • 1. Biochemical activities of the derivatives of dehydrodicaffeic acid dilactone.
    Kumada Y; Naganawa H; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1978 Feb; 31(2):105-11. PubMed ID: 204621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dehydrodicaffeic acid dilactone, an inhibitor of catechol-O-methyl transferase.
    Kumada Y; Naganawa H; Iinuma H; Matsuzaki M; Takeuchi T
    J Antibiot (Tokyo); 1976 Sep; 29(9):882-9. PubMed ID: 1033176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Dopa decarboxylase by caffeic acid and related compounds: structure-activity relationships.
    Rosei MA
    Pharmacol Res Commun; 1987 Oct; 19(10):663-71. PubMed ID: 3441482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
    Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
    Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.
    Marivet MC; Bourguignon JJ; Lugnier C; Mann A; Stoclet JC; Wermuth CG
    J Med Chem; 1989 Jul; 32(7):1450-7. PubMed ID: 2544722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesoionic xanthine analogs as inhibitors of cyclic AMP phosphodiesterase.
    Glennon RA; Rogers ME; Bass RG; Ryan SB
    J Pharm Sci; 1978 Dec; 67(12):1762-5. PubMed ID: 214541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
    Price B; Pyne NJ; Houslay MD
    Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antispasmodic action of 1-diethylaminoethyl-3-(p-methoxybenzyl)-2-quinoxalone (P 201-1) and its inhibitory effect on cyclic 3',5'-nucleotide phosphodiesterase (PDE) activity.
    Hayashi S; Ozawa H
    Chem Pharm Bull (Tokyo); 1975 Apr; 23(4):810-6. PubMed ID: 171085
    [No Abstract]   [Full Text] [Related]  

  • 9. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
    de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
    J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of platelet aggregation and cyclic nucleotide phosphodiesterase (specifically cyclAMP) by 3-hydroxypyridine derivatives].
    Kagan VE; Polianskiĭ NB; Muranov KO; Shvedova AA; Smirnov LD
    Biull Eksp Biol Med; 1984 Apr; 97(4):416-8. PubMed ID: 6202339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrrolo[2,3-d]pyrimidines as inhibitors of cAMP-phosphodiesterase. Structure-activity relationship.
    Klumpp S; Frey M; Kleefeld G; Sauer A; Eger K
    Biochem Pharmacol; 1989 Mar; 38(6):949-53. PubMed ID: 2539163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terferol, an inhibitor of cyclic adenosine 3',5'-monophosphate phosphodiesterase. I. Isolation and characterization.
    Nakagawa F; Enokita R; Naito A; Iijima Y; Yamazaki M
    J Antibiot (Tokyo); 1984 Jan; 37(1):6-9. PubMed ID: 6321424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic studies on selective type 4 phosphodiesterase (PDE 4) inhibitors. 1. Structure-activity relationships and pharmacological evaluation of 1,8-naphthyridin-2(1H)-one derivatives.
    Takayama K; Iwata M; Hisamichi H; Okamoto Y; Aoki M; Niwa A
    Chem Pharm Bull (Tokyo); 2002 Aug; 50(8):1050-9. PubMed ID: 12192136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside.
    Turner NC; Lamb J; Worby A; Murray KJ
    Br J Pharmacol; 1994 Apr; 111(4):1047-52. PubMed ID: 8032589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavonoid compounds are potent inhibitors of cyclic AMP phosphodiesterase.
    Beretz A; Anton R; Stoclet JC
    Experientia; 1978 Aug; 34(8):1054-5. PubMed ID: 212288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benz-fused mesoionic xanthine analogues as inhibitors of cyclic-AMP phosphodiesterase.
    Glennon RA; Gaines JJ; Rogers ME
    J Med Chem; 1981 Jun; 24(6):766-9. PubMed ID: 6265639
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some pentasubstituted quercetin analogs.
    Picq M; Prigent AF; Nemoz G; Pacheco H
    Biochem Pharmacol; 1982 Sep; 31(17):2777-82. PubMed ID: 6291544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
    Lavan BE; Lakey T; Houslay MD
    Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic 3',5'-nucleotide phosphodiesterase in rat skin. II. Biochemical characterization.
    King LE; Solomon SS; Hasimoto K
    J Invest Dermatol; 1975 Jun; 64(6):390-6. PubMed ID: 237964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.